Skip to main content
SpringerLink
Log in

Transarterial Therapies

  • Chapter
  • First Online:
Intrahepatic Cholangiocarcinoma

  • 366 Accesses

Abstract

The incidence of intrahepatic cholangiocarcinoma (ICC) is increasing. Surgical resection is the recommended treatment for patients with localized disease, but a majority of patients still present with unresectable cancer. Despite marginal advances in systemic therapies, the prognosis of unresectable ICC remains dismal. Transarterial therapies, including conventional chemoembolization, drug-eluting bead chemoembolization, and radioembolization, can control tumor progression and potentially improve survival while minimizing adverse impact on the quality of life. This chapter discusses the technical background of the most commonly utilized transarterial therapies, provides an overview on the available literature supporting their use, and discusses triaging patients among the available transarterial therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB. 2008;10(2):77–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–7.

    Article  PubMed  Google Scholar 

  3. Park J, Kim M-H, Kim K, Park DH, Moon S-H, Song TJ, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver. 2009;3(4):298–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Simo KA, Halpin LE, McBrier NM, Hessey JA, Baker E, Ross S, et al. Multimodality treatment of intrahepatic cholangiocarcinoma: a review: multimodality therapy of iCCA. J Surg Oncol. 2016;113(1):62–83.

    Article  PubMed  Google Scholar 

  5. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park J-W, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.

    Article  PubMed  Google Scholar 

  6. Valle J, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomized trials–PubMed –NCBI. Ann Oncol. 2014;25(2):391–8.

    Article  CAS  PubMed  Google Scholar 

  7. Lo C. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71.

    Article  CAS  PubMed  Google Scholar 

  8. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359(9319):1734–9.

    Article  PubMed  Google Scholar 

  9. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497–507.e2.

    Article  PubMed  Google Scholar 

  10. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.

    Article  CAS  PubMed  Google Scholar 

  11. Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Am J Clin Oncol. 2012;35(4):393–8.

    Article  PubMed  Google Scholar 

  12. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271–9.

    Article  PubMed  Google Scholar 

  13. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95(3):588–95.

    Article  PubMed  Google Scholar 

  14. Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol. 2007;17(4):1025–34.

    Article  PubMed  Google Scholar 

  15. Currie B, Soulen M. Decision making: intra-arterial therapies for cholangiocarcinoma—TACE and TARE. Semin Interv Radiol. 2017;34(02):092–100.

    Article  Google Scholar 

  16. National Comprehensive Cancer Network. Hepatobiliary Cancers (Version 1. 2018). Available at: https://www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf.Accessed September 8, 2018.

  17. Rayar M, Sulpice L, Edeline J, Garin E, Levi Sandri GB, Meunier B, et al. Intra-arterial Yttrium-90 Radioembolization combined with systemic chemotherapy is a promising method for downstaging unresectable huge intrahepatic cholangiocarcinoma to surgical treatment. Ann Surg Oncol. 2015;22(9):3102–8.

    Article  CAS  PubMed  Google Scholar 

  18. Chua TC, Liauw W, Saxena A, Chu F, Glenn D, Chai A, et al. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Int. 2010;30(2):166–74.

    Article  PubMed  Google Scholar 

  19. Seidensticker R, Seidensticker M, Doegen K, Mohnike K, Schütte K, Stübs P, et al. Extensive use of interventional therapies improves survival in Unresectable or recurrent intrahepatic cholangiocarcinoma. Gastroenterol Res Pract. 2016;2016:1–13.

    Article  Google Scholar 

  20. Kiefer MV, Albert M, McNally M, Robertson M, Sun W, Fraker D, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer. 2011;117(7):1498–505.

    Article  CAS  PubMed  Google Scholar 

  21. Memon K, Kulik L, Lewandowski RJ, Mulcahy MF, Benson AB, Ganger D, et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol. 2013;58(1):73–80.

    Article  PubMed  Google Scholar 

  22. Chern M-C, Chuang VP, Liang C-T, Lin ZH, Kuo T-M. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with portal vein invasion: safety, efficacy, and prognostic factors. J Vasc Interv Radiol. 2014;25(1):32–40.

    Article  PubMed  Google Scholar 

  23. Yamada R, Nakatsuka H, Nakamura K, Sato M, Itami M, Kobayashi N, et al. Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J. 1980;26(2):81–96.

    CAS  PubMed  Google Scholar 

  24. Ray CE, Edwards A, Smith MT, Leong S, Kondo K, Gipson M, et al. Meta-analysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma. J Vasc Interv Radiol. 2013;24(8):1218–26.

    Article  PubMed  Google Scholar 

  25. Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1989;170:783–6.

    Article  CAS  PubMed  Google Scholar 

  26. Savic LJ, Chapiro J, Geschwind J-FH. Intra-arterial embolotherapy for intrahepatic cholangiocarcinoma: update and future prospects. HepatoBiliary Surg Nutr. 2017;6(1):7–21.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Gaba RC, Lewandowski RJ, Hickey R, Baerlocher MO, Cohen EI, Dariushnia SR, et al. Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. J Vasc Interv Radiol. 2016;27(4):457–73.

    Article  PubMed  Google Scholar 

  28. Hong K. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res. 2006;12(8):2563–7.

    Article  CAS  PubMed  Google Scholar 

  29. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, et al. Prospective randomized study of doxorubicin-eluting bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52.

    Article  PubMed  Google Scholar 

  30. Ariel I. Treatment of inoperable primary pancreatic and liver cancer by the intra-arterial administration of radioactive isotopes (Y90 radiating microspheres). Ann Surg. 1965;162:267–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Salem R, Thurston KG. Radioembolization with Yttrium-90 microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. J Vasc Interv Radiol. 2006;17(10):1571–93.

    Article  PubMed  Google Scholar 

  32. Lewandowski RJ, Geschwind J-F, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology. 2011;259(3):641–57.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. J Vasc Interv Radiol. 2006;17(8):1251–78.

    Article  PubMed  Google Scholar 

  34. Shamimi-Noori S, Gonsalves C, Shaw C. Metastatic liver disease: indications for Locoregional therapy and supporting data. Semin Interv Radiol. 2017;34(02):145–66.

    Article  Google Scholar 

  35. Park S-Y, Kim JH, Yoon H-J, Lee I-S, Yoon H-K, Kim K-P. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol. 2011;66(4):322–8.

    Article  PubMed  Google Scholar 

  36. Burger I, Hong K, Schulick R, Georgiades C, Thuluvath P, Choti M, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol. 2005;16(3):353–61.

    Article  PubMed  Google Scholar 

  37. Vogl TJ, Naguib NNN, Nour-Eldin N-EA, Bechstein WO, Zeuzem S, Trojan J, et al. Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer. 2012;131(3):733–40.

    Article  CAS  PubMed  Google Scholar 

  38. Gusani NJ, Balaa FK, Steel JL, Geller DA, Marsh JW, Zajko AB, et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based Transcatheter Arterial Chemoembolization (TACE): a single-institution experience. J Gastrointest Surg. 2008;12(1):129–37.

    Article  PubMed  Google Scholar 

  39. Herber S, Otto G, Schneider J, Manzl N, Kummer I, Kanzler S, et al. Transarterial Chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2007;30(6):1156–65.

    Article  CAS  PubMed  Google Scholar 

  40. Schiffman SC, Metzger T, Dubel G, Andrasina T, Kralj I, Tatum C, et al. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol. 2011;18(2):431–8.

    Article  PubMed  Google Scholar 

  41. Aliberti C, Benea G, Tilli M, Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol. 2008;31(5):883–8.

    Article  PubMed  Google Scholar 

  42. Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug-eluting bead transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24(4):437–43.

    CAS  PubMed  Google Scholar 

  43. Poggi G, Amatu A, Montagna B, Quaretti P, Minoia C, Sottani C, et al. OEM-TACE: anew therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol. 2009;32(6):1187–92.

    Article  PubMed  Google Scholar 

  44. Mouli S, Memon K, Baker T, Benson AB, Mulcahy MF, Gupta R, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol. 2010;17(2):484–91.

    Article  PubMed  Google Scholar 

  46. Ibrahim SM, Mulcahy MF, Lewandowski RJ, Sato KT, Ryu RK, Masterson EJ, et al. Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer. 2008;113(8):2119–28.

    Article  CAS  PubMed  Google Scholar 

  47. Rafi S, Piduru SM, El-Rayes B, Kauh JS, Kooby DA, Sarmiento JM, et al. Yttrium-90 radioembolization for unresectable standard-chemorefractory intrahepatic cholangiocarcinoma: survival, efficacy, and safety study. Cardiovasc Intervent Radiol. 2013;36(2):440–8.

    Article  PubMed  Google Scholar 

  48. Camacho JC, Kokabi N, Xing M, Prajapati HJ, El-Rayes B, Kim HS. Modified response evaluation criteria in solid tumors and European Association for the Study of the liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following Yttrium-90 radioembolization. J Vasc Interv Radiol. 2014;25(2):256–65.

    Article  PubMed  Google Scholar 

  49. Hoffmann R-T, Paprottka PM, Schön A, Bamberg F, Haug A, Dürr E-M, et al. Transarterial hepatic Yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012;35(1):105–16.

    Article  PubMed  Google Scholar 

  50. Al-Adra DP, Gill RS, Axford SJ, Shi X, Kneteman N, Liau S-S. Treatment of unresectable intrahepatic cholangiocarcinoma with yttrium-90 radioembolization: a systematic review and pooled analysis. Eur J Surg Oncol EJSO. 2015;41(1):120–7.

    Article  CAS  PubMed  Google Scholar 

  51. Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K. Treatment of recurrent intrahepatic cholangiocarcinoma. Br J Surg. 2012;99(12):1711–7.

    Article  CAS  PubMed  Google Scholar 

  52. Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20(12):3779–86.

    Article  PubMed  Google Scholar 

  53. Yang L, Shan J, Shan L, Saxena A, Bester L, Morris DL. Trans-arterial embolization therapies for unresectable intrahepatic cholangiocarcinoma: a systematic review. 2015;6(5):19.

    Google Scholar 

  54. Boehm LM, Jayakrishnan TT, Miura JT, Zacharias AJ, Johnston FM, Turaga KK, et al. Comparative effectiveness of hepatic artery-based therapies for unresectable intrahepatic cholangiocarcinoma: hepatic artery therapy for unresectable ICC. J Surg Oncol. 2015;111(2):213–20.

    Article  PubMed  Google Scholar 

  55. Kim W, Clark TWI, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12(8):965–8.

    Article  CAS  PubMed  Google Scholar 

  56. Devulapalli KK, Fidelman N, Soulen MC, Miller M, Johnson MS, Addo E, et al. Y90 radioembolization for hepatic malignancy in patients with previous biliary intervention: multicenter analysis of hepatobiliary infections. Radiology. 2018;288(3):774–81.

    Article  PubMed  Google Scholar 

  57. Abouchaleh N, Gabr A, Ali R, Al Asadi A, Mora RA, Kallini JR, et al. Y90 radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Med. 2018;59(7):1042–8.

    Article  CAS  PubMed  Google Scholar 

  58. Boeckman HJ. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol Cancer Res. 2005;3(5):277–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Interventional Radiology, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

    Susan Shamimi-Noori & Michael C. Soulen

  2. Department of Radiology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

    Michael C. Soulen

Authors
  1. Susan Shamimi-Noori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael C. Soulen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan Shamimi-Noori .

Editor information

Editors and Affiliations

  1. Wexner Medical Center, The Ohio State University, Columbus, OH, USA

    Timothy M. Pawlik

  2. Wexner Medical Center, The Ohio State University, Columbus, OH, USA

    Jordan M. Cloyd

  3. Wexner Medical Center, The Ohio State University, Columbus, OH, USA

    Mary Dillhoff

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Shamimi-Noori, S., Soulen, M.C. (2019). Transarterial Therapies. In: Pawlik, T., Cloyd, J., Dillhoff, M. (eds) Intrahepatic Cholangiocarcinoma. Springer, Cham. https://doi.org/10.1007/978-3-030-22258-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-22258-1_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-22257-4

  • Online ISBN: 978-3-030-22258-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation